Lupin launches Bumetanide Injection USP in US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Aims to achieve CDMO sales of US$ 400 million by 2028
Subscribe To Our Newsletter & Stay Updated